{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:48:19Z","timestamp":1791031699574,"version":"4.1.0"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The\nantibacterial activities of DK-507k, a novel quinolone, were compared\nwith those of other quinolones: ciprofloxacin, gatifloxacin,\nlevofloxacin, moxifloxacin, sitafloxacin, and garenoxacin (BMS284756).\nDK-507k was as active as sitafloxacin and was as active as or up to\neightfold more active than gatifloxacin, moxifloxacin, and garenoxacin\nagainst\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    , methicillin-susceptible and\nmethicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    , and\ncoagulase-negative staphylococci. DK-507k was as active as or 4-fold\nmore active than garenoxacin and 2- to 16-fold more active than\ngatifloxacin and moxifloxacin against ciprofloxacin-resistant strains\nof\n                    <jats:italic>S. pneumoniae<\/jats:italic>\n                    , including clinical isolates and in\nvitro-selected mutants with known mutations. DK-507k inhibited all\nciprofloxacin-resistant strains of\n                    <jats:italic>S. pneumoniae<\/jats:italic>\n                    at 1\u03bc\ng\/ml. A time-kill assay with\n                    <jats:italic>S. pneumoniae<\/jats:italic>\n                    showed\nthat DK-507k was more bactericidal than gatifloxacin and moxifloxacin.\nThe activities of DK-507k against most members of the family\n                    <jats:italic>Enterobacteriaceae<\/jats:italic>\n                    were comparable to those of ciprofloxacin\nand equal to or up to 32-fold higher than those of gatifloxacin,\nlevofloxacin, moxifloxacin, and garenoxacin. DK-507k was fourfold less\nactive than sitafloxacin and ciprofloxacin against\n                    <jats:italic>Pseudomonas\naeruginosa<\/jats:italic>\n                    , while it was two to four times more potent than\nlevofloxacin, gatifloxacin, moxifloxacin, and garenoxacin against\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    . In vivo, intravenous treatment with\nDK-507k was more effective than that with gatifloxacin and moxifloxacin\nagainst systemic infections caused by\n                    <jats:italic>S. aureus<\/jats:italic>\n                    ,\n                    <jats:italic>S.\npneumoniae<\/jats:italic>\n                    , and\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    in mice. In a mouse model\nof pneumonia due to penicillin-resistant\n                    <jats:italic>S. pneumoniae<\/jats:italic>\n                    ,\nDK-507k administered subcutaneously showed dose-dependent efficacy and\neliminated the bacteria from the lungs, whereas gatifloxacin and\nmoxifloxacin had no significant efficacy. Oral treatment with DK-507k\nwas slightly more effective than that with ciprofloxacin in a rat model\nof foreign body-associated urinary tract infection caused by a\n                    <jats:italic>P.\naeruginosa<\/jats:italic>\n                    isolate for which the MIC of DK-507k was fourfold\nhigher than that of ciprofloxacin. Oral administration of DK-507k to\nrats achieved higher peak concentrations in serum and higher\nconcentrations in cumulative urine than those achieved with\nciprofloxacin. These data indicate the potential advantages of DK-507k\nover other quinolones for the treatment of a wide range of\ncommunity-acquired\ninfections.\n                  <\/jats:p>","DOI":"10.1128\/aac.47.12.3750-3759.2003","type":"journal-article","created":{"date-parts":[[2003,11,24]],"date-time":"2003-11-24T17:53:35Z","timestamp":1069696415000},"page":"3750-3759","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["InVitro and In Vivo Antibacterial Activities of DK-507k, aNovelFluoroquinolone"],"prefix":"10.1128","volume":"47","author":[{"given":"Tsuyoshi","family":"Otani","sequence":"first","affiliation":[{"name":"New\rProduct Research Laboratories I, Daiichi Pharmaceutical Co. Ltd.,\rTokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"New\rProduct Research Laboratories I, Daiichi Pharmaceutical Co. Ltd.,\rTokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Ito","sequence":"additional","affiliation":[{"name":"New\rProduct Research Laboratories I, Daiichi Pharmaceutical Co. Ltd.,\rTokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kurosaka","sequence":"additional","affiliation":[{"name":"New\rProduct Research Laboratories I, Daiichi Pharmaceutical Co. Ltd.,\rTokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Murakami","sequence":"additional","affiliation":[{"name":"New\rProduct Research Laboratories I, Daiichi Pharmaceutical Co. Ltd.,\rTokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Onodera","sequence":"additional","affiliation":[{"name":"New\rProduct Research Laboratories I, Daiichi Pharmaceutical Co. Ltd.,\rTokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Akasaka","sequence":"additional","affiliation":[{"name":"New\rProduct Research Laboratories I, Daiichi Pharmaceutical Co. Ltd.,\rTokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sato","sequence":"additional","affiliation":[{"name":"New\rProduct Research Laboratories I, Daiichi Pharmaceutical Co. Ltd.,\rTokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/340400"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.180.11.2854-2861.1998"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/513953"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/313954"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2032"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.304-310.2000"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1177"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-1-200107030-00012"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2760"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2651-2655.2002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2962-2968.2000"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02355193"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2001.tb01268.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1295-1301.2002"},{"key":"e_1_3_2_16_2","unstructured":"National\nCommittee for Clinical Laboratory Standards. 2000.\nMethods for dilution antimicrobial susceptibility tests for bacteria\nthat grow aerobically; approved standard 5th ed. M7-A5. National\nCommittee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_17_2","first-page":"153","volume":"18","year":"2001","unstructured":"Nicolle, L. E. 2001. Epidemiology of urinary tract infection. Infect. Med.18:153-162.","journal-title":"Infect. Med."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(91)80037-D"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.178.14.4060-4069.1996"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2665-2667.2002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.283.5409.1837"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.489-493.2003"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.4.457"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1520"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/520427"},{"key":"e_1_3_2_26_2","first-page":"387","volume":"53","year":"2000","unstructured":"Yamaguchi, K., S. Miyazaki, F. Kashitani, M. Iwata, and Levofloxacin Surveillance Group. 2000. Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Jpn. J. Antibiot.53:387-408.","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3311-3315.2002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.12.3750-3759.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.12.3750-3759.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:46:16Z","timestamp":1645447576000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.12.3750-3759.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1128\/AAC.47.12.3750-3759.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.12.3750-3759.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"2003-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-08-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}